Connect Biopharma reported a net loss of $52.8 million for the nine months ended September 30, 2026, compared to $40.4 million in the prior year, primarily driven by a significant increase in research and development expenses. Total assets decreased from $56.1 million at year-end 2025 to $27.8 million as of September 30, 2026, reflecting the company's continued cash burn for clinical operations.
Connect Biopharma received a deficiency notice from Nasdaq on November 12, 2026, because its ordinary shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until May 11, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's shares, which continue to trade under the symbol 'CNTB'.
Counterparty
Nasdaq
Term
180 days
“We believe topline results from our Phase 2 Seabreeze STAT asthma and COPD studies mark a significant inflection point in the development of rademikibart as an add-on treatment to rescue bronchodilators and systemic corticosteroids for the treatment of acute exacerbations.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
“We believe these findings support the potential of rademikibart to redefine how acute exacerbations are managed, addressing both the acute event and the 4-week high-risk period following an exacerbation, to improve patient outcomes and reduce the substantial economic burden on healthcare systems.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
Connect Biopharma announced positive topline results from its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation. The study met its primary endpoint, with rademikibart reducing the rate of treatment failure by 81% and eliminating hospital readmissions or emergency department visits for new exacerbations through Week 4. The company plans to engage with the FDA to align on a Phase 3 registrational development program.
Connect Biopharma announced positive topline results from its global Phase 2 study of rademikibart as an add-on treatment for acute asthma exacerbations. The study met its key secondary endpoint with a statistically significant improvement in lung function (FEV1) at Day 7, and while the primary endpoint of treatment failure reduction (66%) did not reach statistical significance due to lower-than-projected event rates, the company plans to engage with the FDA for a Phase 3 program.